Fleshner NE - Search Results

1

Magnetic resonance imaging detected prostate evasive anterior tumours: Further insights.

Edwan GA, Ghai S, Margel D, Kulkarni G, Hamilton R, Toi A, Haidar MA, Finelli A, Fleshner NE. Edwan GA, et al. Among authors: fleshner ne. Can Urol Assoc J. 2015 May-Jun;9(5-6):E267-72. doi: 10.5489/cuaj.2562. Can Urol Assoc J. 2015. PMID: 26029293 Free PMC article.

2

Variation in patterns of practice in diagnosing screen-detected prostate cancer.

Nam RK, Toi A, Trachtenberg J, Jewett MA, Klotz L, Fleshner N, Bagnell PS, Sweet J, Sugar L, Narod SA. Nam RK, et al. BJU Int. 2004 Dec;94(9):1239-44. doi: 10.1111/j.1464-410X.2004.05150.x. BJU Int. 2004. PMID: 15610097

3

Evidence for a biopsy derived grade artifact among larger prostate glands.

Kulkarni GS, Al-Azab R, Lockwood G, Toi A, Evans A, Trachtenberg J, Jewett MA, Finelli A, Fleshner NE. Kulkarni GS, et al. Among authors: fleshner ne. J Urol. 2006 Feb;175(2):505-9. doi: 10.1016/S0022-5347(05)00236-3. J Urol. 2006. PMID: 16406982

4

Surgical wait times for patients with urological cancers: a survey of Canadian surgeons.

Fleshner N, Dranitsaris G, Finelli A, Tsihlias J, Bell D, Gleave M; Canadian surgical wait times (SWAT) initiative. Fleshner N, et al. Can J Urol. 2006 Jun;13 Suppl 3:3-13. Can J Urol. 2006. PMID: 16818006

5

Should finasteride be used to prevent prostate cancer?

Fleshner N, Kulkarni G. Fleshner N, et al. Curr Treat Options Oncol. 2006 Sep;7(5):346-54. doi: 10.1007/s11864-006-0002-0. Curr Treat Options Oncol. 2006. PMID: 16904051 Review.

6

The continuing importance of transrectal ultrasound identification of prostatic lesions.

Toi A, Neill MG, Lockwood GA, Sweet JM, Tammsalu LA, Fleshner NE. Toi A, et al. Among authors: fleshner ne. J Urol. 2007 Feb;177(2):516-20. doi: 10.1016/j.juro.2006.09.061. J Urol. 2007. PMID: 17222623

7

Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL.

Al-Azab R, Toi A, Lockwood G, Kulkarni GS, Fleshner N. Al-Azab R, et al. Urology. 2007 Jan;69(1):103-7. doi: 10.1016/j.urology.2006.09.041. Urology. 2007. PMID: 17270628

8

Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy.

Kulkarni GS, Lockwood G, Evans A, Toi A, Trachtenberg J, Jewett MA, Finelli A, Fleshner NE. Kulkarni GS, et al. Among authors: fleshner ne. Cancer. 2007 Jun 15;109(12):2432-8. doi: 10.1002/cncr.22712. Cancer. 2007. PMID: 17497649 Free article.

9

Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial.

Fleshner N, Gomella LG, Cookson MS, Finelli A, Evans A, Taneja SS, Lucia MS, Wolford E, Somerville MC, Rittmaster R; REDEEM Study Group. Fleshner N, et al. Contemp Clin Trials. 2007 Nov;28(6):763-9. doi: 10.1016/j.cct.2007.05.006. Epub 2007 May 29. Contemp Clin Trials. 2007. PMID: 17573244

10

Optimal management of high-risk T1G3 bladder cancer: a decision analysis.

Kulkarni GS, Finelli A, Fleshner NE, Jewett MA, Lopushinsky SR, Alibhai SM. Kulkarni GS, et al. Among authors: fleshner ne. PLoS Med. 2007 Sep;4(9):e284. doi: 10.1371/journal.pmed.0040284. PLoS Med. 2007. PMID: 17896857 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

642 results

Search Page

Filters